510 related articles for article (PubMed ID: 30578766)
21. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Yan W; Liu G; Scoumanne A; Chen X
Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of METTL14 mediates the elevation of PERP mRNA N
Wang M; Liu J; Zhao Y; He R; Xu X; Guo X; Li X; Xu S; Miao J; Guo J; Zhang H; Gong J; Zhu F; Tian R; Shi C; Peng F; Feng Y; Yu S; Xie Y; Jiang J; Li M; Wei W; He C; Qin R
Mol Cancer; 2020 Aug; 19(1):130. PubMed ID: 32843065
[TBL] [Abstract][Full Text] [Related]
23. Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract][Full Text] [Related]
24. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
25. A lncRNA from the FTO locus acts as a suppressor of the m
Zhang J; Wei J; Sun R; Sheng H; Yin K; Pan Y; Jimenez R; Chen S; Cui XL; Zou Z; Yue Z; Emch MJ; Hawse JR; Wang L; He HH; Xia S; Han B; He C; Huang H
Mol Cell; 2023 Aug; 83(15):2692-2708.e7. PubMed ID: 37478845
[TBL] [Abstract][Full Text] [Related]
26. N
Lin X; Wang F; Chen J; Liu J; Lin YB; Li L; Chen CB; Xu Q
Mil Med Res; 2022 Apr; 9(1):19. PubMed ID: 35418160
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 in colon cancer.
Nakayama M; Oshima M
J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
[TBL] [Abstract][Full Text] [Related]
28. METTL3/YTHDF2 m
Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
[TBL] [Abstract][Full Text] [Related]
30. Mettl3 Deficiency Sustains Long-Chain Fatty Acid Absorption through Suppressing Traf6-Dependent Inflammation Response.
Zong X; Zhao J; Wang H; Lu Z; Wang F; Du H; Wang Y
J Immunol; 2019 Jan; 202(2):567-578. PubMed ID: 30567729
[TBL] [Abstract][Full Text] [Related]
31. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
32. N
Li F; Yi Y; Miao Y; Long W; Long T; Chen S; Cheng W; Zou C; Zheng Y; Wu X; Ding J; Zhu K; Chen D; Xu Q; Wang J; Liu Q; Zhi F; Ren J; Cao Q; Zhao W
Cancer Res; 2019 Nov; 79(22):5785-5798. PubMed ID: 31530567
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.
Zhang Y; Yan W; Chen X
J Biol Chem; 2011 May; 286(18):16218-28. PubMed ID: 21454711
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
Kadioglu O; Saeed M; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Arch Toxicol; 2021 Mar; 95(3):959-974. PubMed ID: 33515271
[TBL] [Abstract][Full Text] [Related]
35. METTL3 potentiates resistance to cisplatin through m
Wei J; Yin Y; Zhou J; Chen H; Peng J; Yang J; Tang Y
J Cell Mol Med; 2020 Oct; 24(19):11366-11380. PubMed ID: 32857912
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
[TBL] [Abstract][Full Text] [Related]
38. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
[TBL] [Abstract][Full Text] [Related]
39. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
Roger L; Jullien L; Gire V; Roux P
J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
[TBL] [Abstract][Full Text] [Related]
40. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N
Wang W; Shao F; Yang X; Wang J; Zhu R; Yang Y; Zhao G; Guo D; Sun Y; Wang J; Xue Q; Gao S; Gao Y; He J; Lu Z
Nat Commun; 2021 Jun; 12(1):3803. PubMed ID: 34155197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
